Prostate cancer is now one of the most diagnosed cancers among men worldwide, and its incidence in India has been rising steadily since last over two decades. Prostate cancer awareness month is observed every September, providing a dedicated period for clinicians, laboratories, and public health bodies to focus attention on a disease that often develops without any early warning sign. Understanding why this observance exists, what drives rising incidence, and how screening works is essential for men across every Indian city, from Ahmedabad and Surat to Kolkata and Hyderabad.
This article outlines the clinical background of prostate cancer, the risk factors supported by current research, the screening tools available, and the reason prostate cancer awareness day and month observances continue to matter for public health.
What Is Prostate Cancer Awareness Month?
This observance falls in September each year, a designation formally proclaimed in the United States in 2001 and now recognized internationally as a period for education, screening promotion, and research support. When is prostate cancer awareness month observed? It is a common search query and the answer is straightforward: it runs for the full month of September, distinct from World Prostate Cancer Day, which is observed separately on 11 June each year.
Both observances share a common goal, and search queries such as "when prostate cancer awareness month is" reflect how many people remain unsure of the distinction. Prostate cancer awareness exists to correct a persistent problem: many men remain unaware of their risk profile, delay screening conversations with their physician, and only seek testing after symptoms have already progressed. Organizations, hospitals and diagnostic laboratories use September month to run screening drives, publish educational material, and encourage men above the recommended screening age to have a conversation with their doctor about testing.
Understanding The Basics of Prostate Cancer
The prostate is a small gland, the size of a walnut, located below the bladder and surrounding part of the urethra in men. It produces fluid that forms part of semen. Prostate cancer develops when cells within the gland begin to grow and divide abnormally. Most prostate cancers are slow-growing and confined to the gland at the time of diagnosis, though a subset can be aggressive and spread to other parts of the body, most commonly the bones and lymph nodes.
A defining clinical feature of prostate cancer is its tendency to progress silently. Early-stage disease frequently produces no symptoms at all, which is precisely why this observance places such emphasis on screening rather than symptom recognition alone.
Prostate Cancer in India: A Rising Health Concern
Historically considered less common in India than in Western countries, prostate cancer incidence has climbed sharply over the past three decades. Data from India's National Cancer Registry Programme, coordinated by the Indian Council of Medical Research, shows a consistent upward trend across multiple urban population-based registries between 1982 and 2016, with annual percentage increases ranging from 1.5% in Mumbai to significantly higher rates in cities such as Ahmedabad.
There are multiple factors explaining this rise:
· Increasing life expectancy, which allows more men to reach the age range where prostate cancer risk climbs sharply.
· Greater urbanization and associated lifestyle changes
· Wider availability of PSA blood testing, leading to more cases being diagnosed than earlier.
· Improved general health literacy and greater willingness among men to discuss urological symptoms with a physician.
The Indian Council of Medical Research estimates 40,000 new prostate cancer cases are reported annually in India, a figure expected to continue rising as the population ages. Urban registries in Delhi, Mumbai and other metropolitan centres report some of the highest age-adjusted incidence rates in the country, underscoring why prostate cancer awareness matters as much in Indian cities as anywhere else.
Diagnostic laboratories across Ahmedabad, Surat, Vadodara, Jaipur, Siliguri, Jamnagar, Indore, Srinagar, Kolkata, Mumbai, and Hyderabad are recording a corresponding rise in PSA test volumes, reflecting both greater screening awareness and the wider availability of laboratory-based testing in metropolitan as well as emerging urban centres.
Risk Factors for Prostate Cancer
No single cause explains why one man develops prostate cancer, and another does not, but research has identified multiple well-established risk factors.
· Age: Risk rises after age 50, with a marked acceleration after 65. Most prostate cancer diagnoses occur in men above this age threshold.
· Family history: Men with a father or brother diagnosed with prostate cancer face a significantly higher lifetime risk, particularly if a relative was diagnosed at a younger age.
· Genetic factors: Inherited mutations, including those affecting the BRCA1 and BRCA2 genes, are associated with increased prostate cancer risk and, in some cases, more aggressive disease.
· Diet and lifestyle: Diets high in processed and red meat, combined with low physical activity and obesity, have been linked to elevated risk in multiple studies.
· Ethnicity: Global data shows variation in incidence and severity across different population groups, though the precise biological mechanisms remain under active research.
None of these factors guarantees that prostate cancer will develop, and men without any identifiable risk factor can still be diagnosed. This uncertainty is exactly why screening, rather than risk-factor assessment alone, forms the backbone of early detection strategy.
Signs and Symptoms to Watch For
Because early prostate cancer is frequently asymptomatic, men are often advised not to wait for symptoms before considering screening. When symptoms do appear, they commonly include:
· Frequent urination, particularly at night
· Weak or interrupted urine flow
· Difficulty starting or stopping urination.
· Blood in the urine or semen
· Discomfort or pain in the pelvic area.
· Unexplained erectile dysfunction
It is worth noting that many of these symptoms overlap with benign prostatic hyperplasia, a common non-cancerous enlargement of the prostate that becomes more frequent with age. Symptom overlap is precisely why laboratory testing, rather than symptoms alone, is required to distinguish between benign and malignant prostate conditions.
Prostate Cancer Screening: The Role of PSA Testing
Prostate-specific antigen, commonly known as PSA, is a protein produced by both normal and cancerous prostate cells. A PSA blood test measures the concentration of this protein in the bloodstream and remains the most widely used screening tool for prostate cancer worldwide.
Elevated PSA levels can indicate the presence of prostate cancer, but they can equally result from benign prostatic hyperplasia, prostatitis, or even recent physical activity. For this reason, a single elevated reading does not confirm cancer; it signals the need for further clinical evaluation.
Unipath Specialty Laboratory offers PSA testing designed to support this evaluation process:
· The standard PSA test measures total prostate-specific antigen levels in the blood, requires no fasting, and typically delivers a same-day report. This test serves as the initial screening tool recommended for most men in the relevant age group. Details are available at the Unipath PSA test page.
· The PSA Profile provides a more detailed picture by measuring Total PSA, Free PSA, and the percentage of Free PSA. This ratio is clinically valuable when total PSA results fall into a borderline range, as it helps physicians assess the likelihood of malignancy more precisely before recommending further investigation. This panel is also available with no fasting requirement and same-day reporting, and full details can be reviewed at the Unipath PSA Profile page.
Both tests are processed under NABL-accredited laboratory protocols, ensuring results that clinicians can rely on for treatment planning and monitoring.
Why Prostate Cancer Awareness Day and Month Observances Matter
These observances serve a function beyond calendar marking. They create a recurring, predictable window during which health systems, employers, and community organizations can coordinate screening camps, publish educational content, and reduce the stigma that often surrounds men's health conversations.
In India specifically, cultural reluctance to discuss urological symptoms has historically delayed diagnosis. Prostate cancer awareness campaigns directly address this gap by normalizing conversations about PSA testing, family history disclosure, and routine screening, particularly among men in the 45 to 70 age bracket who carry the highest baseline risk.
When Should Screening Begin?
Screening guidelines vary slightly across international bodies, but consensus points to the following starting ages:
· Average-risk men: Begin discussing PSA testing with a physician at age 50.
· Men with a family history of prostate cancer: Begin discussion at age 45.
· Men with multiple first-degree relatives affected or known BRCA mutations: Begin discussion as early as age 40.
These are starting points for a conversation with a physician rather than fixed rules, since individual risk profiles vary. A physician will weigh family history, ethnicity, overall health, and personal preference before recommending a specific testing schedule.
This annual observance exists precisely to prompt that first conversation. Men who have never discussed PSA testing with their doctor, or who are unsure whether they fall into a higher-risk category, are encouraged to use September as the occasion to do so.
Unipath Diagnostic Services: Serviceable Cities
Ahmedabad • Surat • Vadodara • Kolkata • Jaipur • Mumbai • Siliguri • Jamnagar
For test bookings and inquiries: Unipath
Disclaimer
Unipath does not represent or warrant that the content or information provided through our blog is accurate, complete, or current, nor that our blog content will be uninterrupted or error-free. We do not guarantee that any defects in our blog content will be corrected or that our server or the server hosting them is free of viruses or other harmful components. Unipath makes no warranties or representations regarding the use of materials in our blog content concerning their correctness, accuracy, adequacy, usefulness, timeliness, reliability, or otherwise, to the fullest extent permitted by applicable law. Information available via our platform and blog content may reference products, programs, or services not available in your region. You understand and acknowledge that your sole and exclusive remedy for any defect in or dissatisfaction with our blog content is to cease using them.
References and Citations
[1] World Health Organization, Cancer Fact Sheet,
[2] National Cancer Institute, Prostate-Specific Antigen (PSA) Test,
[3] American Cancer Society, Prostate Cancer Early Detection,
[4] Indian Council of Medical Research, National Cancer Registry Programme,
[5] Indian Journal of Urology, Descriptive Epidemiology of Prostate Cancer in India 2012–2019,
[6] Mayo Clinic, Prostate Cancer Symptoms and Causes,